Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acorda Therapeutics Inc
NASDAQ ACORQ
Data sourced from
and
and
Acorda Therapeutics Inc Long-Term Debt to Total Assets Ratio 2 year CAGR for the quarter ending September 30, 2023
Acorda Therapeutics Inc Long-Term Debt to Total Assets Ratio 2 year CAGR is NA for the quarter ending September 30, 2023. The long-term debt to total assets ratio measures the proportion of a company's long-term debt to its total assets. It is calculated by dividing the long-term debt by the total assets. This ratio indicates the extent to which a company's assets are financed by long-term debt. A higher ratio suggests a higher level of long-term debt relative to total assets, which can indicate increased financial risk and affect the company's ability to generate returns for its shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Acorda Therapeutics Inc Long-Term Debt to Total Assets Ratio for the quarter ending March 31, 2023 was 0.46.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ACORQ
| CEO | - |
| IPO Date | Feb. 10, 2006 |
| Location | United States |
| Headquarters | 2 Blue Hill Plaza, Pearl River, NY, United States, 10965 |
| Employees | 102 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email